TLC to Present at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit
September 21 2020 - 4:45AM
TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty
pharmaceutical company developing novel nanomedicines to target
areas of unmet medical need, today announced that President Mr.
George Yeh and Chief Medical Officer Dr. George Spencer-Green, MD,
will be presenting at Oppenheimer Fall Healthcare Life Sciences
& Med Tech Summit on Wednesday, September 23, 2020 at 9:10am
ET.
The 40-minute live presentation will include a
company overview and update by Mr. Yeh, with analyses of data on
TLC’s pain programs – TLC599 and TLC590 – by Dr. Spencer-Green.
During the virtual conference, which takes place September 21-23,
2020, TLC will also be participating in one-on-one sessions.
The corporate presentation is available on the
TLC website at www.tlcbio.com in the Investors section, under News
& Events.
About TLC
TLC (NASDAQ: TLC, TWO: 4152) is a clinical-stage
specialty pharmaceutical company dedicated to the research and
development of a diverse, wholly owned portfolio of novel
nanomedicines that maximize the potential of its proprietary
lipid-assembled drug delivery platform (LipAD™), including
BioSeizer® sustained release technology and NanoX™ active drug
loading technology, which are versatile in the choice of active
pharmaceutical ingredients and scalable in manufacturing.
Cautionary Note on Forward-Looking
Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are not
guarantees of future performance and involve a number of risks,
assumptions, uncertainties and factors, including risks that the
outcome of any clinical trial is inherently uncertain and product
candidates may prove to be unsafe or ineffective, or may not
achieve commercial approval. Other risks are described in the Risk
Factors section of TLC’s annual report on Form 20-F for the year
ended December 31, 2019 filed with the U.S. Securities and Exchange
Commission. All forward-looking statements are based on TLC’s
expectations and assumptions as of the date of this press release.
Actual results may differ materially from these forward-looking
statements. Except as required by law, TLC expressly disclaims any
responsibility to update any forward-looking statement contained
herein, whether as a result of new information, future events or
otherwise.
Contact
Dawn Chi / Corporate Communications / dawn@tlcbio.com
Taiwan Liposome (NASDAQ:TLC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Taiwan Liposome (NASDAQ:TLC)
Historical Stock Chart
From Sep 2023 to Sep 2024